Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
Globe Newswire•15/10/2026•07:30 ET
1
Key Highlights
- ➤Phase 3 SELVA pediatric analyses showed improved overall disease severity and lesion characteristics
- ➤Phase 2 TOIVA pediatric analyses showed reduced overall disease severity and lesion bleeding
- ➤QTORIN rapamycin could become the first FDA-approved therapy for both targeted malformations
- ➤Palvella presented previously reported results alongside new pediatric analyses at PeDRA’s 2026 conference
Expert Statements
Wes Kaupinen, Founder and Chief Executive Officer of Palvella Therapeutics
“Microcystic lymphatic malformations and cutaneous venous malformations are serious, rare genetic diseases that can cause bleeding and chronically debilitating complications beginning in childhood and continuing throughout life.”
Wes Kaupinen, Founder and Chief Executive Officer of Palvella Therapeutics
“These encouraging pediatric findings highlight the potential of QTORIN™ rapamycin to address disease manifestations early in life, before these conditions progress and cause further complications.”
Wes Kaupinen, Founder and Chief Executive Officer of Palvella Therapeutics
“We continue to advance QTORIN™ rapamycin with a sense of urgency for both of these serious, rare diseases, with the objective of delivering a first-in-disease FDA-approved therapy that meaningfully improves the lives of affected children and adults.”
Phase 3 SELVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and a Blinded Combined Score of Lesion Height, Vesicle Appearance, and Leaking/Bleeding
Phase 2 TOIVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and Reductions in Lesion Bleeding in Previously Treated Children with Cutaneous Venous Malformations
Get started
Create a free account to read the full story.